Manejo de efectos secundarios: Los efectos secundarios gastrointestinales comunes de los GLP-1 (nuseas, vmitos, diarrea) pueden intensificarse durante los viajes debido a cambios en la dieta y el estrs
A 2024 study published in JAMA Ophthalmology found that semaglutide users faced a higher risk of developing NAION when treated for diabetes or obesity
GLP-1 , :
Drug Manufacturers During the model pre-implementation period in early 2026, CMS negotiated with Novo Nordisk and Eli Lilly to come to agreement on the key parameters of the model, including details about pricing of the model drugs, cost sharing, rebate calculations, access policies (i.e., coverage criteria and prior authorization policies), the length of the agreement, data sharing arrangements, and agreement on lifestyle supports that will be offered
Please keep in mind, if you refill your current medication on or after 7/1/2025, youll need to pay the full cost. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark, along with a few other medications that are generally less effective
While these remarks largely summarize actions FDA has already taken, they highlight compounded GLP-1 products as an area of concern, and this area is likely to be one of continued FDA interest in 2026
